Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $3.74B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.52B 919M Dec/2025
ALKERMES USD 5.53B 909M May/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Biogen USD 26.9B 1.09B Mar/2026
BioMarin Pharmaceutical USD 10.57B 290M May/2026
Bristol-Myers Squibb USD 123.83B 14.02B Mar/2026
Cara Therapeutics USD 366M 338M Sep/2025
Corcept Therapeutics USD 4.32B 654M Mar/2026
Cytokinetics USD 9.25B 1.48B May/2026
Eisai JPY 1.31T 140.95B Dec/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Incyte USD 21.73B 3B May/2026
J&J USD 579.15B 78.91B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 13.34B 800M May/2026
Pfizer USD 148.08B 6.51B May/2026
Prothena USD 514M 11M Dec/2025
PTC Therapeutics USD 6.1B 1.22B Dec/2025
Sarepta Therapeutics USD 2.26B 238M Dec/2025
Ultragenyx Pharmaceutical USD 2.04B 176M May/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Vertex Pharmaceuticals USD 111.03B 2.55B May/2026